STERIS plc

(New York Stock Exchange)
Back to all articles
Bullish +75

STERIS plc (NYSE:STE) Q1 2026 Earnings Call Transcript

AI-generated analysis

πŸ“ˆ STERIS reported Q1 2026 total revenue growth of 9% and constant currency organic revenue growth of 8%, driven by volume and pricing.

πŸ’° Gross margin expanded to 45.3%, up 20 basis points, as positive price and productivity gains offset inflation and tariff costs.

πŸ“Š Adjusted earnings per diluted share rose 15% year-over-year to $2.34 from continuing operations.

πŸš€ Free cash flow for the quarter reached $327 million, a very strong start to fiscal 2026.

🏭 Healthcare capital equipment revenue grew 6% with underlying order growth of 14% and a backlog over $400 million.

πŸ”¬ AST services revenue surged 13%, while Life Sciences consumables grew 8% with backlog up over 50% to $111 million.

πŸ’΅ The company increased its full-year free cash flow outlook by $50 million to $820 million for fiscal 2026.

πŸ‘” CFO Mike Tokich announced his departure after 18 years, with Karen Matson named as the incoming CFO.

Bullish Signals
  • STERIS achieved a 9% total revenue growth and 8% constant currency organic revenue growth in Q1 2026.
  • Gross margin expanded to 45.3%, up 20 basis points, demonstrating strong pricing power and operational efficiency.
  • Adjusted earnings per diluted share increased 15% year-over-year to $2.34 from continuing operations.
  • Free cash flow for the quarter reached $327 million, reflecting strong earnings and working capital improvements.
  • Healthcare segment backlog exceeded $400 million with underlying order growth of 14%, indicating robust demand.
  • AST services revenue grew 13% driven by bioprocessing demand and stable medical device volumes.
  • Life Sciences backlog increased over 50% to $111 million, signaling strong future capital equipment sales.
  • Management raised the full-year free cash flow guidance by $50 million to $820 million for fiscal 2026.
Risk Factors
  • The company increased its tariff cost estimate by $15 million to $45 million for fiscal 2026 due to higher metal and copper tariffs.
  • Management noted general conservatism in maintaining the 6% to 7% constant currency organic revenue guidance despite a strong first quarter.
Full Analysis
STERIS plc reported strong first-quarter fiscal 2026 results, with total revenue growing 9% and constant currency organic revenue rising 8%. Gross margins expanded to 45.3%, driven by pricing power and productivity gains that outpaced inflation and tariff costs. Adjusted earnings per diluted share increased 15% year-over-year to $2.34, reflecting improved operational leverage and geographic mix. The company highlighted robust performance across its Healthcare, AST, and Life Sciences segments. Healthcare capital equipment revenue grew 6% with a backlog exceeding $400 million, while AST services surged 13%. Life Sciences consumables drove growth, and backlog increased over 50% to $111 million. Free cash flow for the quarter reached $327 million, marking a strong start to the fiscal year. Management updated its full-year outlook, anticipating as-reported revenue growth of 8% to 9% due to favorable currency rates, while maintaining constant currency organic revenue guidance at 6% to 7%. The company increased its free cash flow forecast by $50 million to $820 million for fiscal 2026. CFO Mike Tokich announced his departure after 18 years, with Karen Matson set to succeed him as the new CFO.